ライフサイエンスコーパス: xanomeline

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 choline receptor (mAChR) orthosteric agonist xanomeline (1) and the putative M1 mAChR allosteric agon

2 ency, and selectivity comparable to those of xanomeline 2 in the muscarinic tests investigated.

3 The authors studied xanomeline, a relatively selective muscarinic type 1 and

4 rs tested the hypothesis that treatment with xanomeline, an M1 selective muscarinic cholinergic agoni

5 ing administration of the muscarinic ligands xanomeline and 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquin

6 rinic acetylcholine receptor (mAChR) agonist xanomeline and the human M1 mAChR expressed in Chinese h

7 te administration of both an M1R/M4R agonist xanomeline and the M1R antagonist olanzapine was able to

8 ese results support further investigation of xanomeline as a novel approach to treating schizophrenia

9 2 patients, two taking placebo and 10 taking xanomeline at a dose of 25 mg t.i.d. (N = 4), 50 mg t.i.

10 the non-subtype-selective agonist carbachol, xanomeline demonstrated M1 mAChR binding that was resist

11 Subjects treated with xanomeline did significantly better than subjects in the

12 , thiopilocarpine, hexylthio-TZTP as well as xanomeline effectively stimulated PI hydrolysis, but mil

13 rate Alzheimer's disease received placebo or xanomeline for 6 months.

14 the cognitive test battery, subjects in the xanomeline group showed improvements most robustly in me

15 Xanomeline, hexylthio-TZTP and thiopilocarpine were rela

16 pare orthosteric agonists, acetylcholine and xanomeline, M1 allosteric agonists AC-42 (4-n-butyl-1-[4

17 Xanomeline may reduce breakdown of cholinergic neuron me

18 al analysis of the inhibition by atropine of xanomeline-mediated functional responses indicated a pos

19 study, the authors examined the efficacy of xanomeline on clinical outcomes in subjects with schizop

20 M1R-rich brain areas by the M1R/M4R agonist xanomeline, or the antipsychotics olanzapine (M1R antago

21 psychotic activity of the muscarinic agonist xanomeline prompted us to investigate the effects of N-d

22 ue, it was determined that administration of xanomeline robustly stimulated in vivo PI hydrolysis and

23 ocesses involved in memory and cognition and xanomeline's beneficial clinical effects on cognition in

24 Therefore, these data demonstrate that xanomeline selectively activates in vivo PI hydrolysis,

25 For the combined group of patients taking xanomeline, there was a significant decrease in the chol

26 selective muscarinic receptor agonist (SMRA) xanomeline to stimulate in vivo phosphoinositide (PI) hy

27 which may involve unusually avid binding of xanomeline to the receptor.

28 he mechanism or mechanisms of interaction of xanomeline with the M1 mAChR is particularly important i

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。